Relenza (Zanamivir) News and Research

RSS
Relenza (zanamivir) is an anti-viral drug, for persons aged 7 years and older for the treatment of uncomplicated influenza illness. This product is approved to treat type A and B influenza, the two types most responsible for flu epidemics. Clinical studies showed that for the drug to be effective, patients needed to start treatment within two days of the onset of symptoms. The drug seemed to be less effective in patients whose symptoms weren't severe or didn't include a fever. Relenza is approved for preventive use, to decrease the risk of developing influenza illness, for persons aged 5 and older. Relenza is a powder that is inhaled twice a day for five days from a breath-activated plastic device called a Diskhaler for treatment of influenza. For preventive use to reduce the risk of getting influenza, Relenza is inhaled once daily for 10 to 28 days as prescribed by a healthcare provider.
Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Tamiflu resistant flu on the rise: Study

Tamiflu resistant flu on the rise: Study

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark announces results from NT-300 Phase 2B-3 trial on influenza

New development in flu prevention & treatment

New development in flu prevention & treatment

Has the NHS procured too many swine flu shots?

Has the NHS procured too many swine flu shots?

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

FDA urges consumers to exercise care on online H1N1 drug products

FDA urges consumers to exercise care on online H1N1 drug products

Members of Blue Shield of California to receive administrative costs of the H1N1 virus vaccine

Members of Blue Shield of California to receive administrative costs of the H1N1 virus vaccine

Virulence of pandemic H1N1 virus analyzed

Virulence of pandemic H1N1 virus analyzed

U.S. moves forward with preparations for H1N1 vaccination campaign

U.S. moves forward with preparations for H1N1 vaccination campaign

WHO to recommend countries stop testing for H1N1

WHO to recommend countries stop testing for H1N1

International health experts hold two-day H1N1 meeting

International health experts hold two-day H1N1 meeting

Concern over case of drug resistant swine flu

Concern over case of drug resistant swine flu

U.S. Vaccine Advisory Committee considers response to H1N1 spread

U.S. Vaccine Advisory Committee considers response to H1N1 spread

Swine flu tally has U.S. top and Australia 6th

Swine flu tally has U.S. top and Australia 6th

H1N1 spread continues worldwide; first death in Asia confirmed

H1N1 spread continues worldwide; first death in Asia confirmed

Reuters examines WHO efforts to fight H1N1 in developing countries

Reuters examines WHO efforts to fight H1N1 in developing countries